AZN - AstraZeneca PLC

NYSE - Nasdaq Real Time Price. Currency in USD
42.95
+0.08 (+0.19%)
As of 1:32PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close42.87
Open43.07
Bid42.87 x 3100
Ask42.88 x 800
Day's Range42.80 - 43.06
52 Week Range34.11 - 43.06
Volume2,414,050
Avg. Volume5,058,670
Market Cap106.819B
Beta (3Y Monthly)0.46
PE Ratio (TTM)50.53
EPS (TTM)0.85
Earnings DateN/A
Forward Dividend & Yield1.40 (3.29%)
Ex-Dividend Date2019-02-28
1y Target Est45.77
Trade prices are not sourced from all markets
  • The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores
    Zacksyesterday

    The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores

    The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores

  • PhaseBio Stock Up on Positive Data From PB2452 Phase I Study
    Zacksyesterday

    PhaseBio Stock Up on Positive Data From PB2452 Phase I Study

    PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.

  • Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer
    Zacksyesterday

    Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer

    Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

  • Why You Should Buy ABBV Stock for Income and Value
    InvestorPlaceyesterday

    Why You Should Buy ABBV Stock for Income and Value

    Today, I'd like to discuss the outlook for AbbVie (NYSE:ABBV), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been hammered following its earning report of Jan. 25.Source: Shutterstock * Top 7 Service Sector Stocks That Will Pay You to Own Them There could be further price volatility and weakness in the ABBV stock price in the coming weeks, pushing it toward the low-$70's or even mid-$60's level. However, it is a company with robust growth prospects and respectable dividends that may deserve a place in a diversified portfolio.Therefore, if you already own AbbVie shares, you might want to hold your position. That said, within the parameters of your portfolio allocation and risk/return profile, you may consider placing a stop loss at about 5-7% below the current price point. Expect nearer-term trading to be choppy at best.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIf you are an experienced investor in the options market, you may want to protect your portfolio with a covered call or possibly a put option spread with a 3-month time horizon. If you do not yet hold ABBV, you may want to wait several weeks to buy into the stock at the next dip.With all of that in mind, here's a deeper look into at AbbVie stock. A Hiccup in the Robust Fundamental StoryIn 2013, Abbott Laboratories (NYSE:ABT) spun off its research-based pharmaceuticals business, creating AbbVie, an independent biopharmaceutical company. Abbott decided to retain the branded generic pharmaceuticals, diagnostics, medical devices and nutrition.Meanwhile, AbbVie took control of the development and commercialization of a range of brands, including Humira, its flagship drug used to treat autoimmune diseases, Imbruvica, which differentiates between cancer cells and regular cells, and Synthroid, a replacement for a hormone normally produced by the thyroid gland.The company's financials and growth metrics over the past five years have been impressive and ABBV was in a strong financial position heading into 2019, with hopes of a higher share price during the first quarter.However, in January, AbbVie's fourth-quarter earnings release weighed heavily on the stock. For starters, the company missed the consensus on revenue. Its earnings per share of $1.90 was below the expected number of $1.94. The next day, the stock fell by 6% and that decline has intensified over the past two months.ABBV's quarterly report also showed that the international sales of Humira fell by almost 15% year over year, mostly as a result of 'biosimilar' competition in Europe, which makes up three-quarters of the overseas Humira business. In October 2018, its patent in the European Union (E.U) expired.The U.S. Food and Drug Administration (FDA) refers to biosimilars as "highly similar to an FDA-approved biological product … [that has] no clinically meaningful differences in terms of safety and effectiveness." Although Wall Street had already known about this sales decline in Europe, when coupled with the other question marks in the earnings report, it was enough to increase the selling pressure on the stock.It is also possible that investors got worried about the potential fall in Humira revenue when the drug comes off patent in 2023 in the U.S. It is important to emphasize that AbbVie's revenue from the drug will not decline to nothing when the biosimilars hit the market in 2023. What will most likely happen is that as the company's pricing power decreases, the revenue will also gradually decline.Therefore, many analysts feel that ABBV shares offer value and that any bad news that is specific to Humira is already baked into the stock price. Value PlayWhen markets penalize biopharma stocks, it can take some time for them to recover. However, for patient long-term investors, the returns can be significant -- especially when the company boasts several other current drugs, as well promising ones in the pipeline.At present, AbbVie's other major products include: * AndroGel, a testosterone replacement therapy. * Creon, a pancreatic enzyme therapy to treat exocrine pancreatic insufficiency. * Duopa and Duodopa, gels to treat Parkinson's disease. * Viekira Pak, which treats chronic hepatitis C. * Zinbryta, to treat multiple sclerosis.Analysts are also expecting a slew of new products in 2020, such as next-generation immunology drugs. These drugs and others that are being developed and commercialized, highlight how impressive the potential growth story could be in the next few years.ABBV trades at a trailing price-to-earnings (P/E) ratio of 21. This number is rather modest when compared with the P/E ratios of several competitors, including AstraZeneca (NYSE:AZN) with a P/E of 49.9, Pfizer (NYSE:PFE) with a P/E of 25.2, and Merck (NYSE:MRK) with a P/E of 34.8. Reinvesting the Sweet Dividend Yield of ABBV stockIncome investors know that they can compound their returns through reinvesting dividends from high-yielding shares. AbbVie also offers investors a healthy dividend yield of about 5.4%, another reason why I believe the stock belongs in a capital-growth portfolio.Since its spin-off from Abbott Laboratories in 2013, ABBV has increased dividends every year -- a trend that is likely to continue. The next dividend payment is scheduled for May 15, 2019, with an ex-dividend date of April 12.It would not be wrong to call AbbVie a cashflow machine; as of Dec. 31, the company had a free cash flow of $3.27 billion. This strength not only gives shareholders conviction that the dividends are safe, but also provides the company with enough flexibility to, for example, make acquisitions to offset any further Humira revenue decline (especially in the U.S. when the drug comes off patent in 2023). The Bottom Line on AbbVie StockLike most biopharma stocks, AbbVie is a high-momentum stock. In other words, when the broader markets go up or when the company's earnings beat expectations, both investors and momentum traders tend to hit the "buy" button fast, expecting superior gains within days or weeks.However, if markets suffer a decline or if the company cannot keep up with the rising expectations, investors' risk appetite decreases fast and these stocks can fall much harder than less volatile stocks. * 7 Financial Stocks to Invest In Today The market has punished Abbvie stock since the start of the year. The stock may continue to struggle through much of 2019. However, patient ABBV bulls will probably be proven right to believe in the management's commitment to create shareholder value and to further grow the company both organically and through acquisitions. In the meantime, they can continue to collect high dividends.As of this writing, Tezcan Gecgil did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Financial Stocks to Invest In Today * 7 Single-Digit P/E Stocks With Massive Upside * 5 Chip Stocks on the Rise Compare Brokers The post Why You Should Buy ABBV Stock for Income and Value appeared first on InvestorPlace.

  • Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?
    Zacksyesterday

    Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?

    Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?

  • Benzingayesterday

    The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 18) AstraZeneca plc (NYSE: AZN )(received orphan drug ...

  • Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
    Zacks2 days ago

    Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

    Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

  • Top Research Reports for Merck, Adobe & Broadcom
    Zacks2 days ago

    Top Research Reports for Merck, Adobe & Broadcom

    Top Research Reports for Merck, Adobe & Broadcom

  • Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
    Zacks2 days ago

    Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

    Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.

  • Business Wire2 days ago

    First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes

    FARXIGA reduced major adverse cardiovascular events by 16% in patients who had a prior heart attack

  • AstraZeneca Up This Year on New Drugs & Pipeline Progress
    Zacks2 days ago

    AstraZeneca Up This Year on New Drugs & Pipeline Progress

    AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

  • 3 Dividend Stocks That Should Pay You the Rest of Your Life
    Motley Fool3 days ago

    3 Dividend Stocks That Should Pay You the Rest of Your Life

    These dividend stocks could send you checks for a lifetime.

  • 3 Top Diabetes Stocks to Watch in March
    Motley Fool4 days ago

    3 Top Diabetes Stocks to Watch in March

    Keep your eyes on these three hot diabetes stocks this month.

  • Benzinga4 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

    Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support. Here are some key catalysts that can move biotech stocks in the ...

  • Guardant Health (GH) Q4 2018 Earnings Conference Call Transcript
    Motley Fool5 days ago

    Guardant Health (GH) Q4 2018 Earnings Conference Call Transcript

    GH earnings call for the period ending December 31, 2018.

  • AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag
    Zacks5 days ago

    AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat, Revenues Lag

    AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in Q4. However, revenues fall shy of estimates.

  • Merck's Keytruda Gets EU Approval for Difficult Lung Cancer
    Zacks5 days ago

    Merck's Keytruda Gets EU Approval for Difficult Lung Cancer

    Merck (MRK) receives approval for Keytruda's combo therapy for first-line treatment of metastatic squamous non-small cell lung cancer population in Europe.

  • Here's Why Momentum Investors Will Love Astrazeneca (AZN)
    Zacks6 days ago

    Here's Why Momentum Investors Will Love Astrazeneca (AZN)

    Does Astrazeneca (AZN) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Is Britain Headed for a Soft Brexit? 5 Picks
    Zacks6 days ago

    Is Britain Headed for a Soft Brexit? 5 Picks

    Following May's fresh legislative defeat, Britain could exit the EU while retaining access to its common market.

  • Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down
    Zacks7 days ago

    Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down

    Inovio Pharmaceuticals (INO) reports results for fourth quarter of 2018 wherein loss and revenues both miss estimates.

  • Reuters8 days ago

    BioNTech hires banks for IPO worth up to $800 million - sources

    BioNTech, Europe's largest unlisted biotech firm by staff numbers, has hired banks to prepare for an initial public offering (IPO) worth as much as $800 million (611.3 million pounds) as early as this year, people familiar with the plan told Reuters. Bank of America and JP Morgan have been retained as global coordinators for the planned listing on the U.S. Nasdaq exchange some time in the fourth quarter or in early 2020, the sources said. BioNTech, which has previously said it was looking at a future public listing, said it would continue to explore various financing options, including a possible IPO, within the context of its financing needs and the market environment.

  • 5 Active Mutual Funds Worth Their Expenses
    InvestorPlace8 days ago

    5 Active Mutual Funds Worth Their Expenses

    Active mutual funds get a bad rap. Although, some of that criticism is well deserved. The truth is most active managers fail to beat their benchmarks and chronically underperform. Because of this, many investors have turned to index investing and ETFs to get their market fix.The reason for so much indexing love, and perhaps the cause of why active mutual funds tend to fail, comes down to cost.Active funds generally cost more than their cheap indexing rivals. Those higher costs are a hurdle that managers must clear before they can tack on any gains. Think about it. An active mutual fund with an expense ratio of 1.25% needs to make that 1.25% first, before it can chase its benchmark. With ETFs charging just 0.03% these days, the ball is in their court.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut here's the thing -- not all active mutual funds are bad. In fact, many can and do clear their higher fee hurdles, offer higher active shares and actually *gasp* beat their beat their benchmarks over time. It's here that investors can get higher returns. Adding a smattering of these active funds to a cheap indexed core portfolio can do wonders. * The 10 Best Stocks to Buy for the Bull Market's Anniversary With that, here are five active mutual funds worthy of their expenses.Source: Shutterstock T. Rowe Price QM U.S. Small-Cap Growth Equity (PRDSX)Expense Ratio: 0.79% or $79 per $10,000 invested. Minimum Investment: $2,500One of the best places to find active mutual funds worth owning is in the small- and mid-cap spaces. In this market cap size, there's more chance to values and great growth stories as Wall Street analysts tend to ignore smaller stocks. And that's just what the T. Rowe Price QM U.S. Small-Cap Growth Equity (MUTF:PRDSX) has been doing since the late 1990s. It looks like one of the best funds in its niche.Fund manager Sudhir Nanda combs through the broader small-cap world by using screens tied to valuation, quality and momentum. Those stocks that meet the standards are included in the portfolio's holdings. Right now, that's 300 stocks, including EXACT Sciences Corporation (NASDAQ:EXAS) and Fair Isaac (NASDAQ:FICO). However, no stock makes up more than around 1.25% of PRDSX's portfolio.The best part is that Nanda and his screens have made PRDSX a top performer.Since 2006 when Nanda became the head manager, PRDSX has managed to beat the S&P 500 by an average 2.7 percentage points a year. Moreover, when looking at its benchmark- the MSCI US Small Cap Growth Index- PRDSX has beaten it over the one-, three-, five- and 10-year periods. And pretty significantly at that.Nanda and his team at PRDSX are clearly adding value for investors and are worth the active mutual funds' 0.79% expense ratio. Fidelity Focused Stock (FTQGX)Expense Ratio: 0.82% Minimum Investment: NoneOne of the best parts about index investing is the diversification involved. So, you want your active fund to perform differently than an index, it can't look like an index. One of the other great ways to beat the market is by concentrating your picks. So-called high-conviction funds only hold a handful of stocks that the managers believe will provide great returns. Instead of 500 stocks, you only get 40. And in that, you get better returns.The Fidelity Focused Stock (MUTF:FTQGX) is one of the best funds at turning concentrated bets into bigger gains.As the name implies, FTQGX is focused on a few stocks. In this case, the active mutual fund will own between 30 and 80 different names. These can be either growth or value stocks that the managers think will outperform over the longer haul. Lately, the active mutual fund's focus has been on growth names, holding only 38 stocks. Healthcare and technology stocks dominate the mutual fund's top holdings. These include Amazon (NASDAQ:AMZN) and AstraZeneca (NYSE:AZN).The fund's results prove that it's high-conviction strategy is a winner.FTQGX has crushed the S&P 500 over its life. The fund has managed to beat the broader index over the 3-, 5- and 10-year periods. Perhaps the biggest win for the mutual fund came last year. As the S&P lost money, the Fidelity Focused Stock mutual fund managed to produce a positive 5.32% return. * 7 Top Stocks to Buy From Goldman Sachs' Secret Portfolio When it comes to active mutual funds, FTQGX is one of the best funds to buy.Source: Shutterstock Vanguard International Growth Fund Investor Shares (VWIGX)Expense Ratio: 0.45% Minimum Investment: $3,000Vanguard is the king of indexing. But the asset manager is pretty good when it comes to active mutual funds as well. A prime example is the Vanguard International Growth Fund Investor Shares (MUTF:VWIGX).International stocks have been a mixed bag since the recession. Like U.S. stocks in the previous decade -- marked by the dot com crash and great recession -- international equities are nearing a so-called lost decade of performance. Indexing in the stocks of Europe, Japan and other developed markets would have netted you basically nothing. Active managers, however, have done much better. VWIGX over the past 10 years, managed to return an average annual 9.52%. That's nearly double its benchmark -- the MSCI World ex-USA Index.VWIGX's excess return comes from its strategy.The fund is dually managed by Baillie Gifford Overseas and Schroder Investment Management at roughly a 60/40 spilt. Baillie Gifford runs a more traditional growth sleeve for its assets. This means paying for stocks that are rapidly growing sales. This has it diving head-first into emerging markets and international tech firms. Schroder's is more of value seeker and uses growth-at-a-reasonable price, or GARP, investing strategy to find bargains. The combination provides fast growth with some stability. That allows for less volatility and overall better returns.And with a Vanguard-low expense ratio, investors are able to keep more of those returns -- even for this actively managed mutual fund.Source: Shutterstock Metropolitan West Total Return Bond (MWTRX)Expense Ratio: 0.67% Minimum Investment: $5,000Bonds and fixed-income investments tend to be another area that active mutual funds can outperform their indexes. That's because many bond indices are rigid in their construction and/or are weighted on the amount of debt. Total return or go-anywhere bond funds allow their mangers to buy what they view is a best bet at the time. Because of that, top active managers in the fixed income space can and do earn returns above their benchmark indexes.That includes the Metropolitan West Total Return Bond (MUTF:MWTRX).The $71 billion behemoth is surprisingly nimble for a bond fund and can really go anywhere to find a good total return -- that is price appreciation and dividends. According to its mandate, the mangers at MWTRX can own corporate bonds, collateralized debt obligations, mortgage-related and asset-backed securities, bank loans, money-market securities, swaps, futures, municipal securities, options, credit default swaps, private placements and restricted securities. And it doesn't matter if they have interest rates that are fixed, variable or floating. It really can own it all.And owning it all has been a great strategy. * 7 Dow Jones Stocks to Buy MWTRX has managed to crush its benchmark -- the Bloomberg Barclays U.S. Aggregate Bond Index- by a mile. Over the last 10-years, the active mutual fund has returned 5.51% annualized. This is versus just a 3.48% annualized return for the index. No wonder why the fund has a four-star rating and a Gold recommendation from Morningstar.Source: Studio Incendo via Flickr (Modified) Matthews Pacific Tiger Fund (MAPTX)Expense Ratio: 1.08% Minimum Investment: $2,500Emerging markets hold plenty of promise and those in Asia are particularly primed for growth. However, how do you know which is a good nation or bad, or which stocks can capitalize the best to take advantage of the potential. Separating the wheat from the chaff takes an active touch and a real boots on the ground approach.That's exactly what the Matthews Pacific Tiger Fund (MUTF:MAPTX) does.Matthews Asia only does Asian-focused mutual funds and separate managed accounts. This expertise has allowed the firm to before better than many of its benchmarks and indexes. This includes MAPTX -- one of its flagship funds.MAPTX bets on stocks in countries and markets in Asia, including developed, emerging, and frontier countries but excluding Japan. However, the bulk of the fund's holdings lie within developing and emerging markets. Sure, China is included … but so is Thailand, Malaysia and Indonesia. This different concentration as well as the fact that the fund only holds about 60 stocks has allowed MAPTX beat its benchmark -- the MSCI All Country Asia ex Japan Index -- over the long haul. Over the last 5- and 10-year periods, MAPTX has beaten the index by roughly 1.5 percentage points per year. Since its inception in 1994, it's more than doubled its performance.Clearly, Matthews has the winning formula in its specialty and has managed to clear its expense ratio hurdle with ease.At the time of writing, Aaron Levitt did not have a position in any of the active mutual funds mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy Under 15x Earnings * 7 Dark Horse Stocks That Deserve Your Attention in 2019 * 5 Disruptive Technologies That Are Moving Too Fast Compare Brokers The post 5 Active Mutual Funds Worth Their Expenses appeared first on InvestorPlace.

  • How the UK Makes Money
    Investopedia8 days ago

    How the UK Makes Money

    The United Kingdom has one of the strongest economies in the world thanks to the strength of its services, manufacturing construction and tourism sectors.

  • Here's Why Seres Therapeutics Stock Soared Today
    Motley Fool9 days ago

    Here's Why Seres Therapeutics Stock Soared Today

    A new collaboration with AstraZeneca could give microbiome-based medicine a big lift.

  • Seres teams up with AstraZeneca to explore microbiome benefits in cancer treatment
    American City Business Journals9 days ago

    Seres teams up with AstraZeneca to explore microbiome benefits in cancer treatment

    Microbiome-focused biotech Seres Therapeutics is teaming up with drug giant AstraZeneca to explore how the trillions of bacteria in a person’s gut could help fight cancer.